

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Guideline scope

Intrapartum care for high-risk women

Topic

The Department of Health in England has asked NICE to develop a guideline for intrapartum care of 'high risk' women, including risk assessment and place of birth.

This guideline will sit alongside NICE's existing guideline on the [care of healthy women and their babies during childbirth](#), and cover labours in which either the pregnant woman or her baby is at high risk of adverse outcomes because of a medical condition affecting the woman or an obstetric complication.

For more information about why this guideline is being developed, and how the guideline will fit into current practice, see the [context](#) section.

Who the guideline is for

- Pregnant women, their families and carers and the public.
- Obstetricians, midwives, anaesthetists and other healthcare professionals involved in the care of women in labour, including in maternity services.
- Providers and commissioners of maternity services.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#).

Equality considerations

NICE has carried out [an equality impact assessment](#) during scoping. The assessment:

- 27 • lists equality issues identified, and how they have been addressed
- 28 • explains why any groups are excluded from the scope, if this was done.

29 The guideline will look at inequalities relating to women who have
30 complicating social factors who find it difficult to access and/or derive full
31 benefit from the care available, such as recent migrants, travellers, women
32 who have difficulty understanding and speaking English, and women with
33 disabilities.

34 **1 What the guideline is about**

35 This guideline covers aspects of intrapartum care for women who are
36 identified before or during labour as being at high risk of adverse outcomes.

37 **1.1 Who is the focus?**

38 **Groups that will be covered**

39 Women who go into labour who are at term (from 37⁺⁰ weeks) and at high risk
40 of adverse outcomes for themselves and/or their baby.

41 Two main groups of women in labour are the focus of this guideline:

- 42 • women in labour who are identified as high risk before or during labour
43 because of pre-existing medical conditions
- 44 • women in labour who are identified as high risk because of obstetric
45 complications, women who have no antenatal care, and women in labour
46 whose baby is identified before or during labour to be at high risk of
47 adverse outcomes.

48 **Groups that will not be covered**

- 49 • Women in labour whose baby is identified antenatally to be at high risk of
50 adverse outcomes because the baby has a congenital disorder.
- 51 • Women in preterm labour.
- 52 • Women in labour who are identified to be at high risk before or during
53 labour because of personal or social circumstances.

- 54 • Women in labour without known medical conditions who have a caesarean
55 section that is planned as part of antenatal care.

56 **1.2 Settings**

57 **Settings that will be covered**

- 58 • Hospital obstetric units, midwifery units located alongside obstetric units,
59 and community settings including freestanding midwifery units and home.

60 **1.3 Activities, services or aspects of care**

61 **Key areas that will be covered**

- 62 • Place of birth for women at high risk of adverse outcomes in labour,
63 including transfer of care for women who are identified as being at low risk
64 at the start of labour who develop a complication or obstetric emergency.
- 65 • Risk assessment and intrapartum care for women who are at high risk of
66 adverse outcomes because of medical conditions:
- 67 – women with cardiac disease (for example women with mitral valve
68 regurgitation)
 - 69 – women with respiratory disease (including asthma and those with long-
70 term steroid medication)
 - 71 – women with non-thrombophilic haematological disorders
 - 72 – women with subarachnoid haemorrhage and/or arterio-venous
73 malformations of the brain and platelet disorders
 - 74 – women with renal problems
 - 75 – women with liver disease
 - 76 – women who are obese.
- 77 • Risk assessment and intrapartum care for women at high risk of adverse
78 outcomes not as a result of medical conditions:
- 79 – care of women with obstetric complications:
 - 80 ◇ women with sepsis
 - 81 ◇ women who have babies with shoulder dystocia

- 82 ◇ women with pyrexia
- 83 ◇ women with malpresentation or malposition of the baby in labour
- 84 (including breech presentation)
- 85 ◇ women with intrapartum haemorrhage
- 86 ◇ women who are in labour after 42 weeks of pregnancy
- 87 – care of women during vaginal birth after a previous caesarean section
- 88 – care of women with a small-for-dates baby or a large-for-dates baby
- 89 – care of women who present in labour who have had no antenatal care.

90 **Areas that will be covered by incorporation from or updating of the NICE**
91 **guideline on [intrapartum care](#)**

- 92 • Care of women with delay in the third stage of labour (retained placenta).
- 93 • Care of women who have a postpartum haemorrhage.
- 94 • Monitoring (management when cardiotocography is abnormal) during
- 95 labour.

96 **Areas that will not be covered**

97 The following populations will not be covered in this guideline because:

- 98 • they are covered in other NICE guidelines
- 99 • it is planned that the area of intrapartum care will be part of updated scopes
- 100 of previously published NICE guidelines
- 101 • they are covered in related guidelines that are NICE-accredited (Royal
- 102 College of Obstetricians and Gynaecologists [RCOG] Green-top
- 103 Guidelines)
- 104 • they cover only a very small group of women presenting in labour.

105 Explanations for exclusion are given alongside each population only when
106 these are related to published NICE guidelines or RCOG Green-top
107 guidelines.

- 108 • Care of women with the following medical conditions:
- 109 – women with mental health problems requiring medication

- 110 – women who are taking anti-coagulants (covered in: [Thrombosis and](#)
- 111 [embolism during pregnancy and the puerperium, reducing the risk](#)
- 112 [\[RCOG Green-top Guideline No. 37a\]](#))
- 113 – women with musculoskeletal disorders including back problems
- 114 – women with hepatitis B or C, or with HIV
- 115 – women with previous myomectomy or hysterotomy
- 116 – women with pelvic girdle pain
- 117 – women with neurological disorders such as epilepsy
- 118 – women with neuromuscular disorders such as multiple sclerosis
- 119 – women with sickle cell disease (covered in: [Sickle cell disease in](#)
- 120 [pregnancy, management of \[RCOG Green-top Guideline No. 61\]](#))
- 121 – women with thyroid disease
- 122 • Care of women with the following obstetric complications:
- 123 – women with multiple pregnancy
- 124 – women with hypertension in pregnancy
- 125 – women with a 3rd or 4th degree tear (covered in: [Third- and fourth-](#)
- 126 [degree perineal tears, management \[RCOG Green-top Guideline No.](#)
- 127 [29\]](#))
- 128 – women with diabetes in pregnancy
- 129 – women with obstetric cholestasis (covered in: [Obstetric Cholestasis](#)
- 130 [\[RCOG Green-top Guideline No. 43\]](#))
- 131 – women in suspected preterm labour (covered in: [Preterm labour and](#)
- 132 [birth](#). NICE guideline expected November 2015)
- 133 – women with cord prolapse (covered in: [Umbilical Cord Prolapse \[RCOG](#)
- 134 [Green-top Guideline No. 50\]](#))
- 135 – women who collapse in labour (covered in: [Maternal Collapse in](#)
- 136 [Pregnancy and the Puerperium \[RCOG Green-top Guideline No. 56\]](#))
- 137 – women with suspected amniotic fluid embolism (covered in: [Maternal](#)
- 138 [collapse in pregnancy and the puerperium \[RCOG Green-top Guideline](#)
- 139 [No. 56\]](#))
- 140 – women infected by Group B streptococcus (GBS) in pregnancy

- 141 – women with planned caesarean section for reasons other than maternal
- 142 medical disorders
- 143 – women with obstetric complications in a previous pregnancy, labour
- 144 and/or birth including:
 - 145 ◇ stillbirth or neonatal death
 - 146 ◇ baby with neonatal encephalopathy
 - 147 ◇ pre-eclampsia needing preterm birth
 - 148 ◇ placental abruption with adverse outcome
 - 149 ◇ eclampsia
 - 150 ◇ uterine rupture
 - 151 ◇ postpartum haemorrhage needing additional treatment or blood
 - 152 transfusion
 - 153 ◇ retained placenta requiring manual removal in theatre
 - 154 ◇ shoulder dystocia
- 155 • Women with personal and social complications.

156 **1.4 Economic aspects**

157 We will take economic aspects into account when making recommendations.
158 We will develop an economic plan that states for each review question (or key
159 area in the scope) whether economic considerations are relevant, and if so
160 whether this is an area that should be prioritised for economic modelling and
161 analysis. We will review the economic evidence and carry out economic
162 analyses, using an NHS and personal social services (PSS) perspective as
163 appropriate.

164 **1.5 Key issues and questions**

165 While writing this scope, we have identified the following key issues, and key
166 review questions related to the intrapartum care of high risk women:

167 **Review questions for intrapartum care for women at high risk of adverse**
168 **outcomes because of medical conditions**

- 169 1 What is the most appropriate planned place of birth for women with
170 known risk factors for adverse outcomes in labour for the woman and/or
171 her baby?
- 172 2 What are the most appropriate referral criteria for women with known risk
173 factors for adverse outcomes in labour for the woman and/or her baby?

174 Women with cardiac disease:

- 175 3 What is the most appropriate fluid management regimen for women with
176 different types of cardiac disease who are in labour?
- 177 4 What is the safety of regional analgesia compared with systemic narcotic
178 analgesia for women with cardiac disease who are in labour?
- 179 5 How should the second stage of labour be managed for women with
180 cardiac disease?
- 181 6 What is the most appropriate mode of birth for women with cardiac
182 disease?
- 183 7 How should the third stage of labour be managed for women with
184 cardiac disease?

185 Women with respiratory disease:

- 186 8 How should women with asthma be cared for during labour in order to
187 prevent breathlessness?
- 188 9 Which forms of analgesia are the safest for women with asthma?
- 189 10 How should labour be managed in women on long-term steroid therapy?

190 Women with non-thrombophilic haematological disorders:

- 191 11 How should fetal monitoring be managed for women who are at
192 increased risk of haemorrhage because of non-thrombophilic
193 haematological disorders?
- 194 12 What additional measures are needed to ensure the safety of regional
195 analgesia in women with non-thrombophilic haematological disorders?

196 13 How should the third stage of labour be managed for women who are at
197 increased risk of haemorrhage because of non-thrombophilic
198 haematological disorders?

199 Women with subarachnoid haemorrhage and/or arterio-venous malformations
200 of the brain and platelet disorders:

201 14 How should the second stage of labour be managed for women with
202 subarachnoid haemorrhage and/or arterio-venous malformations of the
203 brain and platelet disorders?

204 Women with renal problems:

205 15 What is the most effective treatment for achieving fluid balance during
206 labour for women with renal diseases?

207 16 What is the appropriate intrapartum care for women with renal diseases?

208 Women with liver disorders:

209 17 What is the most effective and safe method of analgesia for women with
210 liver disorders?

211 18 How should labour be managed for women with liver disorders?

212 Women who are obese:

213 19 How should fetal monitoring be managed during labour for women who
214 are obese?

215 20 What is the value of assessing fetal presentation and position early in
216 labour for women who are obese to predict mode of birth?

217 21 How should progress in labour be assessed in women who are obese?

218 22 What interventions improve the effectiveness of regional analgesia in
219 women who are obese?

220 23 How should the second stage of labour be managed for women who are
221 obese in order to improve maternal and fetal outcomes?

222 **Review questions for women at high risk of adverse outcomes in labour**
223 **not as a result of medical conditions**

- 224 24 How should fetal monitoring be managed during labour for women at
225 high risk of adverse outcomes in labour for the woman and/or her baby?
- 226 25 What maternal observations should be performed for women at high risk
227 of adverse outcomes in labour for the woman and/or her baby?
- 228 26 Does type of analgesia influence outcomes for the woman and/or her
229 baby?
- 230 27 What thromboprophylaxis should be offered to women at high risk of
231 adverse outcomes in labour for the woman and/or her baby?
- 232 28 What immediate postpartum care should be provided for women
233 following adverse outcomes in labour for the woman and/or her baby?

234 Women with obstetric complications

235 Women with sepsis:

- 236 29 What are the symptoms and signs of sepsis for women in labour?
- 237 30 What are the most effective and safest methods of analgesia and
238 anaesthesia for women with sepsis in labour?
- 239 31 What diagnostic tools are most effective when sepsis is suspected for
240 women in labour?
- 241 32 What is the most clinical and cost effective antimicrobial therapy for
242 women with sepsis in labour?
- 243 33 How should fetal monitoring be managed for women with sepsis who
244 present in labour?
- 245 34 What is the most appropriate mode of birth for women with sepsis?
- 246 35 What is the most appropriate timing of birth for women with sepsis?
- 247 36 What is the most appropriate management for women with sepsis in the
248 first 24 hours after the birth?

249 Women who have babies with shoulder dystocia:

- 250 37 What risk factors are indicative of shoulder dystocia?

251 38 What are the effective manoeuvres in management of shoulder dystocia
252 in labour?

253 Women with pyrexia:

254 39 Does the use of anti-pyretics improve maternal and neonatal outcomes?

255 40 Does the use of fetal blood sampling (in conjunction with electronic fetal
256 monitoring) improve neonatal outcomes?

257 41 Does investigating the cause of pyrexia in labour improve maternal and
258 neonatal outcomes?

259 Women with malpresentation or malposition of the baby in labour

260 42 What is the best method of delivering the head where there is a breech
261 presentation?

262 43 How should the second stage of labour be managed for women with an
263 unborn baby in breech presentation?

264 Women with intrapartum haemorrhage:

265 44 What is the most appropriate mode of delivery for women with
266 intrapartum haemorrhage?

267 Women in labour after 42 weeks of pregnancy (including spontaneous labour):

268 45 What monitoring of the woman and baby should be carried out during
269 labour for women in labour after 42 weeks of pregnancy?

270 Women having a vaginal birth after a previous caesarean section:

271 46 What is the most appropriate planned place of birth for women who give
272 birth vaginally and have had a previous caesarean section?

273 47 How should fetal monitoring be managed during labour for women who
274 give birth vaginally and have had a previous caesarean section?

275 Women with a small-for-dates baby or a large-for-dates baby:

276 48 How should fetal monitoring be managed during labour for women with a
277 small-for dates baby?

278 49 How should the second stage of labour be managed for women with a
279 large-for-dates baby?

280 Women who present in labour with no antenatal care

281 50 What are the most appropriate systems for risk assessment and
282 management for women who present in labour with no antenatal care?

283 Women who were considered to be low risk at the start of labour but who
284 develop complications

285 51 When and where should care be transferred for women who were
286 considered low risk at the start of labour but develop complications after
287 the start of labour?

288 **1.6 Main outcomes**

289 The main outcomes that will be considered when searching for and assessing
290 the evidence are:

291 For the woman:

292 1 mortality

293 2 major morbidities (such as genital tract trauma, blood loss)

294 3 mode of birth

295 4 women's experience of labour and birth (including psychological
296 wellbeing)

297 5 length of hospital stay and high dependency unit/intensive care unit
298 admission

299 6 type of analgesia

300 7 other major morbidity specific to the topic.

301 For the baby:

302 8 mortality

- 303 9 major neonatal morbidity (such as hypoxic ischaemic encephalopathy,
304 brain injuries and respiratory complications)
305 10 neonatal infection
306 11 neonatal intensive care unit admission
307 12 long-term child developmental outcomes (such as cerebral palsy).

308 **2 Links with other NICE guidance and NICE** 309 **Pathways**

310 **2.1 NICE guidance**

311 **NICE guidance that will be incorporated unchanged in this guideline**

- 312 • [Intrapartum care](#) (2014) NICE guideline CG190

313 **NICE guidance about the experience of people using NHS services**

314 NICE has produced the following guidance on the experience of people using
315 the NHS. This guideline will not include additional recommendations on these
316 topics unless there are specific issues related to the intrapartum care of
317 women at high risk of adverse outcomes:

- 318 • [Patient experience in adult NHS services](#) (2012) NICE guideline CG138
- 319 • [Service user experience in adult mental health](#) (2011) NICE guideline
320 CG136
- 321 • [Medicines adherence](#) (2009) NICE guideline CG76

322 **NICE guidance in development that is closely related to this guideline**

323 NICE is currently developing the following guidance that is closely related to
324 this guideline:

- 325 • [Preterm labour and birth](#). NICE guideline. Publication expected November
326 2015
- 327 • [Sepsis: the recognition, diagnosis and management of severe sepsis](#). NICE
328 guideline. Publication expected July 2016.

329 2.2 NICE quality standards

- 330 • [Neonatal jaundice](#) (2014) NICE quality standard QS57
- 331 • [Asthma: diagnosis and management of asthma](#) (2013) NICE quality
- 332 standard QS25
- 333 • [Antenatal care](#) (2012) NICE quality standard QS22


334 2.3 NICE Pathways

335 [NICE Pathways](#) bring together all related NICE guidance and associated
336 products on a topic in an interactive topic-based flow chart.

337 When this guideline is published, the recommendations will be added to a new
338 NICE pathway, which will be accessible from the existing pathway on
339 [intrapartum care](#). An outline pathway, based on this scope, is included below.
340 It will be adapted and more detail added as the recommendations are written
341 during guideline development.

342 The new pathway will link to existing pathways that cover intrapartum care
343 that are outside the scope of this guideline such as [diabetes in pregnancy](#) and
344 [hypertension in pregnancy](#).

Intrapartum care for high risk women overview



NICE guideline: Intrapartum care for high-risk women - draft scope for consultation (13 August to 11 September 2015)

346 **3 Context**

347 **3.1 Key facts and figures**

348 Risk assessment and planning are key components of pregnancy care for
349 pregnant women, so that any factors that are likely to have a negative impact
350 on the pregnancy and/or birth can be identified in a timely manner. Care can
351 then be delivered in order to maximise the chances of good outcomes for both
352 the woman and her baby. This assessment and planning starts at the
353 antenatal booking appointment and continues throughout pregnancy at each
354 antenatal visit. During labour, routine monitoring of the woman and her unborn
355 baby and of the progress of labour is a continuation of the risk-screening
356 process. Findings from these assessments will impact on the plan of care for
357 labour and may result in changes to the plan being made antenatally or during
358 labour if new complications are identified.

359 A pregnancy is 'high risk' when the likelihood of an adverse outcome for the
360 woman and/or the baby is greater than that of the 'normal population'. A
361 labour is 'high risk' when the adverse outcomes arise in association with
362 labour.

363 The risk can be identified before pregnancy, during pregnancy or during
364 labour. It can arise from a variety of processes, and can affect the woman
365 and/or the baby. Examples are described in the following paragraphs.

- 366 • A woman may have a pre-existing medical condition that can be made
367 worse by the physiological changes that occur in labour. The 2014
368 MBACE-UK report on [Saving lives, improving mothers' care](#) states that
369 there were approximately 10 maternal deaths per 100,000 women giving
370 birth in the UK in 2010–12. Of these, two-thirds were the result of physical
371 or mental health problems in pregnancy (indirect deaths) and only one-third
372 resulted from direct complications of pregnancy such as bleeding. Cardiac
373 disease remains the largest single cause of indirect maternal deaths.

- 374 • Pregnancy-related (obstetric) problems can develop that increase the risk
375 of adverse labour and/or birth outcomes. Again, these can lead to mortality:
376 one-third of maternal deaths resulting from direct complications of
377 pregnancy were associated with thrombosis and thromboembolism, 15%
378 with genital tract sepsis and 15% with haemorrhage.
- 379 • A woman can enter labour with no identified complications and be
380 considered 'low risk' but problems may arise during labour that can be
381 associated with adverse outcomes. These problems may develop gradually
382 over the course of labour or arise as acute emergencies. The 2011
383 Birthplace in England study found that 10.1% of women considered 'low
384 risk' before labour had one or more complicating conditions identified at the
385 start of care in labour. The study also reported the following rates of
386 adverse outcomes for women categorised as low risk at the end of
387 pregnancy: intrapartum section, 5.8%; third-or fourth-degree perineal
388 trauma, 2.7%; blood transfusion, 0.9%; admission of the baby to a neonatal
389 intensive care unit, 2.1%. Although maternal mortality is rare, complications
390 in labour cause significant morbidity, and can have long-term physical and
391 psychological consequences. Furthermore, maternity claims represent the
392 highest value and second highest number of clinical negligence claims
393 reported to the NHS Litigation Authority (NHSLA).
- 394 • The 2014 MBRRACE-UK report showed that 22% of women who died in
395 labour were overweight and 27% were obese. Women who receive little or
396 no antenatal care are at increased risk of adverse birth outcomes, largely
397 as a result of the lack of opportunity for full assessment and antenatal and
398 intrapartum care planning.

399 **3.2 Current practice**

400 Women with risk factors for an adverse labour outcome that are known before
401 the onset of labour will enter labour with a plan of care that includes the place
402 of birth, level of intrapartum maternal and fetal monitoring, strategies for
403 intrapartum analgesia and treatment and interventions specific to the woman's

404 condition. The woman is also likely to have made an individualised birth plan
405 detailing her preferences for labour.

406 Variation in care can arise in any of these areas, depending on the severity of
407 the condition or complication and the anticipated level of associated risk.

408 Variation may also result from differences in birth unit protocols, opinions and
409 preferences of senior medical staff and local availability of resources.

410 If the risk either arises or is identified after the woman has gone into labour,
411 consideration still needs to be given to the changes to routine intrapartum
412 care that are needed, although the options may be more limited depending on
413 the setting. Transfer may be needed to a place of birth with the necessary
414 facilities to care for the woman and her baby.

415 **3.3 Policy, legislation, regulation and commissioning**

416 **Legislation, regulation and guidance**

- 417 • [Children and Families Act](#). October 2014

418 **Commissioning**

- 419 • [Commissioning of Maternity Services](#). July 2012

420 One of the issues to be covered in this guideline that may impact on
421 commissioning is transfer of intrapartum care from one place of care to
422 another for women at high risk of adverse outcomes.

423 **Further information**

This is the draft scope for consultation with registered stakeholders. The consultation dates are 13 August to 11 September 2015. The guideline is expected to be published in November 2017.

You can follow progress of the [guideline](#). Our website has information about how [NICE guidelines](#) are developed.

424